Topic: Biomarkers

Bladder Cancer Journal Vol. 6, Issue 4

Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.

Read More

PC Markers Algorithm

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at University of California, San Diego, discusses how the PC Markers algorithm simplifies the process of screening, diagnosing, and treating prostate cancer for primary care physicians and urologists. Family practitioners and internists order 90% of PSA tests in men, but may be overwhelmed with other health concerns in their patients when deciding to refer them to urologists. Dr. Crawford discusses data behind the identification of PSA >1.5ng/ml as the trigger point for screening, with a significant increase in cancer diagnosis between 1.5-4.0ng/ml. He also notes that 73% of PSA tests are still below the 1.5ng/ml threshold of eligibility for further PCa screening. Dr. Crawford then details the development of the PC Markers algorithm and how it combines a range of blood, urine, and imaging biomarkers to better inform primary care physicians and urologists in how to proceed with prostate cancer screening, diagnosis, and treatment.

Read More

Prevalence of Criteria for Genetic Testing According to the National Comprehensive Cancer Network Guidelines in a Contemporary Cohort of Post-Prostatectomy Men with Intermediate and High-Risk Prostate Cancer: The Henry Ford Health System Experience

Zade Roumayah details the results of a study at the Henry Ford Health System examining the prevalence of National Comprehensive Cancer Network criteria for genetic testing in post-prostatectomy men who had intermediate- to high-grade prostate cancer. With around a 50% response rate, the team found that around 27% of men fit these criteria, in categories including family history of break & ovarian cancer, having two or more family members with a variety of cancer types, and personal cancer history.

Read More

Join the GRU Community

- Why Join? -